Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel <i>In Vivo</i> Model of Acquired Cetuximab Resistance

Abstract

These data suggest that the use of dual EGFR-HER2 kinase inhibitors can enhance responses to cetuximab, perhaps in part due to downregulation of 611-CTF. This study conducted in a novel in vivo model provides a mechanistic rationale for ongoing phase I clinical trials using this combination treatment modality.